154 related articles for article (PubMed ID: 20556834)
1. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease.
Muntoni S; Rojkind M; Muntoni S
World J Gastroenterol; 2010 Jun; 16(23):2889-94. PubMed ID: 20556834
[TBL] [Abstract][Full Text] [Related]
2. A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis.
Wang YJ; Lee SD; Hsieh MC; Lin HC; Lee FY; Tsay SH; Tsai YT; Hu OY; King ML; Lo KJ
J Hepatol; 1994 Nov; 21(5):872-7. PubMed ID: 7890905
[TBL] [Abstract][Full Text] [Related]
3. Colchicine treatment of liver fibrosis.
Nikolaidis N; Kountouras J; Giouleme O; Tzarou V; Chatzizisi O; Patsiaoura K; Papageorgiou A; Leontsini M; Eugenidis N; Zamboulis C
Hepatogastroenterology; 2006; 53(68):281-5. PubMed ID: 16608040
[TBL] [Abstract][Full Text] [Related]
4. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial.
Trinchet JC; Beaugrand M; Callard P; Hartmann DJ; Gotheil C; Nusgens BV; Lapiere CM; Ferrier JP
Gastroenterol Clin Biol; 1989 Jun; 13(6-7):551-5. PubMed ID: 2753302
[TBL] [Abstract][Full Text] [Related]
5. [The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: a randomized, double blind, placebo controlled clinical trial].
Yin SS; Wang BE; Wang TL; Jia JD; Qian LX
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):467-70. PubMed ID: 15329205
[TBL] [Abstract][Full Text] [Related]
6. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
7. Colchicine in the treatment of cirrhosis of the liver.
Kershenobich D; Vargas F; Garcia-Tsao G; Perez Tamayo R; Gent M; Rojkind M
N Engl J Med; 1988 Jun; 318(26):1709-13. PubMed ID: 3287167
[TBL] [Abstract][Full Text] [Related]
8. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
9. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests.
Trinchet JC; Hartmann DJ; Pateron D; Laarif M; Callard P; Ville G; Beaugrand M
J Hepatol; 1991 Mar; 12(2):139-44. PubMed ID: 1711064
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cirrhosis with colchicine. A double-blind randomized trial.
Kershenobich D; Uribe M; Suárez GI; Mata JM; Pérez-Tamayo R; Rojkind M
Gastroenterology; 1979 Sep; 77(3):532-6. PubMed ID: 378754
[TBL] [Abstract][Full Text] [Related]
11. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C.
Angelico M; Cepparulo M; Barlattani A; Liuti A; Gentile S; Hurtova M; Ombres D; Guarascio P; Rocchi G; Angelico F
Aliment Pharmacol Ther; 2000 Nov; 14(11):1459-67. PubMed ID: 11069317
[TBL] [Abstract][Full Text] [Related]
12. Procollagen-type III-peptide serum concentrations in chronic persistent and chronic active hepatitis and in cirrhosis of the liver and their diagnostic value.
Raedsch R; Stiehl A; Waldherr R; Mall G; Gmelin K; Götz R; Walker S; Czygan P; Kommerell B
Z Gastroenterol; 1982 Dec; 20(12):738-43. PubMed ID: 7164528
[TBL] [Abstract][Full Text] [Related]
13. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.
Castilla A; Prieto J; Fausto N
N Engl J Med; 1991 Apr; 324(14):933-40. PubMed ID: 1900574
[TBL] [Abstract][Full Text] [Related]
16. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
[TBL] [Abstract][Full Text] [Related]
17. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.
Kweon YO; Goodman ZD; Dienstag JL; Schiff ER; Brown NA; Burchardt E; Schoonhoven R; Brenner DA; Fried MW
J Hepatol; 2001 Dec; 35(6):749-55. PubMed ID: 11738102
[TBL] [Abstract][Full Text] [Related]
18. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.
Rambaldi A; Gluud C
Cochrane Database Syst Rev; 2001; (3):CD002148. PubMed ID: 11687017
[TBL] [Abstract][Full Text] [Related]
19. Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: relationship to liver histology.
Trinchet JC; Hartmann DJ; Pateron D; Munz-Gotheil C; Callard P; Ville G; Beaugrand M
Alcohol Clin Exp Res; 1992 Apr; 16(2):342-6. PubMed ID: 1590556
[TBL] [Abstract][Full Text] [Related]
20. Colchicine in chronic hepatitis B: a pilot study.
Floreani A; Lobello S; Brunetto M; Aneloni V; Chiaramonte M
Aliment Pharmacol Ther; 1998 Jul; 12(7):653-6. PubMed ID: 9701529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
